Evercore Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Cuts Target Price to $285

Evercore analyst Vijay Kumar maintains $Becton Dickinson & Co(BDX.US)$ with a buy rating, and adjusts the target price from $290 to $285.According to TipRanks data, the analyst has a success rate of 4

Moomoo News44minutes ago · Ratings

Evercore ISI Adjusts Price Target on Becton, Dickinson to $285 From $290, Maintains Outperform Rating

Becton, Dickinson (BDX) has an average outperform rating and a price target range of $240 to $325, according to analysts polled by Capital IQ. Price: 229.86, Change: +0.59, Percent Change: +0.26

MT Newswires07:42 ET

BD's (BDX) New Research Tool to Aid Single-Cell Analysis

Yahoo FinanceJun 27 12:51 ET

With Becton, Dickinson and Company (NYSE:BDX) It Looks Like You'll Get What You Pay For

Becton, Dickinson and Company's (NYSE:BDX) price-to-earnings (or "P/E") ratio of 49.1x might make it look like a strong sell right now compared to the market in the United States, where around half of

Simply Wall StJun 27 08:02 ET

BD Has Commercially Launched New Single-cell Research Tool To Help Scientists Better Understand How Molecular Machinery Within A Cell Functions And It Regulates Changes That Can Lead To Cancer And Other Diseases

BD Has Commercially Launched New Single-cell Research Tool To Help Scientists Better Understand How Molecular Machinery Within A Cell Functions And It Regulates Changes That Can Lead To Cancer And Oth

BenzingaJun 26 06:46 ET

New BD Research Tool Helps Scientists Study Cells That Are Often Key Culprits in the Development of Cancer and Infectious Diseases

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell...

PR NewswireJun 26 06:45 ET